Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$80.18 - $156.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)3.19M
Market Cap
$13.89B
Enterprise Value$23.05B
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 01, 2025EPS Estimate
0.94Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-7.72
Shares Outstanding158,400,000
10 Day Avg. Volume2,310,819
30 Day Avg. Volume3,190,583
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)9.50
P/FCF Ratio9.50
Enterprise Value/Market Cap1.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.05
Enterprise Value/Ebitda-31.79
Forecast
1Y Price Target
$129.00Price Target Upside47.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Business DiversificationIllumina believes its financial performance will be partially driven by its multiomics portfolio and roadmap, aiming for high single-digit annual revenue growth by 2027.
Cost Savings InitiativesILMN announced $100M in incremental cost savings initiatives to help mitigate the China impact, including optimization of stock-based compensation and acceleration of productivity measures globally.
Bears Say
Market CompetitionConcerns on NIH funding levels and increasing competition from Roche persist, likely presenting further downside risks to this year’s guide.
Regulatory ChallengesThe Chinese government moved to ban the import of ILMN sequencers as part of a broader retaliation to increased tariffs.
Revenue DeclineChina revenue for ILMN has declined for six consecutive quarters, with the country now representing a smaller portion of total revenue.
---
Ownership Overview
0.26% Insiders
30.96% Mutual Funds
39.80% Other Institutional Investors
5.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $80.18 and its highest was $156.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $13.89B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is May 01, 2025 which is in 36 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Feb 06, 2025. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.913 by $0.037.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of $3.104 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 0.94.
How many shares outstanding does Illumina have?
Illumina has 158,400,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $0.95 in its last earnings report, beating expectations of $0.913. Following the earnings report the stock price went down -9.56%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
---
Illumina Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$129.00 (47.38% Upside)
$129.00 (47.38% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.00%
12-Months-Change
Fundamentals
Return on Equity
-30.11%
Trailing 12-Months
Asset Growth
-37.66%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
---
ILMN Company Deck
---
ILMN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with notable achievements in revenue growth and strategic partnerships but also highlighted challenges, particularly in the China market and a decline in certain regional revenues.Read More>---
ILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
---
ILMN Stock 12 Month Forecast
Average Price Target
$129.00
▲(47.38% Upside)
Technical Analysis
Pacific Biosciences
―
Qiagen
―
Crispr Therapeutics AG
―
Guardant Health
―
Twist Bioscience
―
Best Analysts Covering ILMN
1 Year
1 Year Success Rate
24/32 ratings generated profit
1 Year Average Return
+15.93%
reiterated a buy rating 22 days ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +15.93% per trade.
---